<DOC>
	<DOCNO>NCT00004288</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess safety efficacy olsalazine , dimer 5-aminosalicylic acid , men ankylose spondylitis unresponsive nonsteroidal anti-inflammatory drug physiotherapy .</brief_summary>
	<brief_title>Phase II Pilot Study Olsalazine Ankylosing Spondylitis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients treat daily olsalazine . The dose increase week protocol dose reach . Supplemental acetaminophen allow ; nonsteroidal anti-inflammatory drug continue unchanged . Concurrent sulfasalazine prohibit .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Olsalazine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Meets modify New York diagnostic criterion Active disease , i.e. , morning stiffness 30 minute Failed experienced nonlifethreatening reaction prior sulfasalazine No significant hematologic , hepatic , renal disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>ankylose spondylitis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>